Daptomycin. Fresh from the Pipeline

Aarti Raja; J. LaBonte; J. Lebbos; P. Kirkpatrick

Daptomycin. Fresh from the Pipeline

Aarti Raja
, J. LaBonte
, J. Lebbos
, P. Kirkpatrick

Department of Biological Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?

Original language	American English
Journal	Nature Reviews Drug Discovery
State	Published - Dec 1 2003

Disciplines

Biology

Cite this

@article{a08c055cc3fa40f9b054219e460d5e40,

title = "Daptomycin. Fresh from the Pipeline",

abstract = " In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?",

author = "Aarti Raja and J. LaBonte and J. Lebbos and P. Kirkpatrick",

year = "2003",

month = dec,

day = "1",

language = "American English",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

}

TY - JOUR

T1 - Daptomycin. Fresh from the Pipeline

AU - Raja, Aarti

AU - LaBonte, J.

AU - Lebbos, J.

AU - Kirkpatrick, P.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?

AB - In September 2003, daptomycin (Cubicin; Cubist Pharmaceuticals) — the first member of a new class of antibiotics — was approved by the US FDA for the treatment of infections caused by Gram-positive bacteria. Will its ability to treat infections resistant to many current antibiotics lead to significant market success?

UR - https://nsuworks.nova.edu/cnso_bio_facarticles/70

M3 - Article

SN - 1474-1776

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

ER -

Daptomycin. Fresh from the Pipeline

Abstract

Disciplines

Other files and links

Fingerprint

Cite this